Progesterone and 1,25-dihydroxyvitamin D 3 inhibit endometrial cancer cell growth by upregulating semaphorin 3B and semaphorin 3F

Molecular Cancer Research

Volumn 9, Issue 11, 2011, Pages 1479-1492

  Nguyen, Huyen ^a   Ivanova, Vessela S ^a   Kavandi, Leyla ^a   Rodriguez, Gustavo C ^b   Maxwell, George L ^c,d   Syed, Viqar ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CASPASE 3; GELATINASE A; GELATINASE B; PLEXIN; PLEXIN A3; PROGESTERONE; SEMAPHORIN; SEMAPHORIN 3B; SEMAPHORIN 3F; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ARTICLE; ATTENUATION; CANCER CELL; CANCER INHIBITION; CELL INVASION; CELL LINE; COLONY FORMATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; UPREGULATION;

CELL LINE, TUMOR; CELL SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; PROGESTERONE; RECEPTORS, CELL SURFACE; SEMAPHORINS; TRANSFECTION; UP-REGULATION; VITAMIN D;

EID: 81755162051     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-11-0213     Document Type: Article

References (51)

1. Moxley KM, McMeekin DS. Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents. Oncologist 2010;15:1026-33.
2. American Cancer Society. Estimated new cancer cases and deaths by sex. US, 2010.
3. Ryan A, Susil B, Jobling T, Oehler M. Endometrial cancer. Cell Tissue Res 2005;322:53-61. (Pubitemid 41677655)
4. Hecht J, Mutter G. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783-91. (Pubitemid 46630943)
5. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
6. Nowell PC. Mechanisms of tumor progression. Cancer Res 1986;46:2203-7. (Pubitemid 16120666)
7. Weinberg R. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 1989;49:3713-21. (Pubitemid 19197385)
8. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-41. (Pubitemid 23098782)
9. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 1992;355:846-7.
10. Pasterkamp RJ, Kolodkin AL. Semaphorin junction: making tracks toward neural connectivity. Curr Opin Neurobiol 2003;13:79-89. (Pubitemid 36197931)
11. Gaur P, Bielenberg DR, Samuel S, Bose D, Zhou Y, Gray MJ, et al. Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis. Clin Cancer Res 2009;15:6763-70.
12. Neufeld G, Shraga-Heled N, Lange T, Guttmann-Raviv N, Herzog Y, Kessler O. Semaphorins in cancer. Front Biosci 2005;10:751-60.
13. Sekido Y, Bader S, Latif F, Chen JY, Duh FM, Wei MH, et al. Human semaphorins A (V) and (IV) reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci U S A 1996;93:4120-5. (Pubitemid 26146727)
14. Xiang R, Hensel C, Garcia D, Carlson HC, Kok K, Daly MC, et al. Isolation of the human semaphorin III/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer. Genomics 1996;32: 39-48.
15. Roche J, Boldog F, Robinson M, Robinson L, Varella-Garcia M, Swanton M, et al. Distinct 3p21.3 deletions in lung cancer, analysis of deleted genes and identification of a new human semaphorin. Oncogene 1996;12:1289-97. (Pubitemid 26128926)
16. Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999;99:71-80. (Pubitemid 29468631)
17. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell 1997;90:739-51. (Pubitemid 27357965)
18. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin is a semaphorin III receptor. Cell 1997;90:753-62. (Pubitemid 27357966)
19. Yazdani U, Terman JR. The semaphorins. Genome Biol 2006;7:211-4.
20. Joseph D, Saydmohammed M, Ho SM, Syed V. Hormonal regulation and distinct functions of semaphorin-3Band semaphorin-3F in ovarian cancer. Mol Cancer Ther 2010;9:499-509.
21. Tse C, Xiang RH, Bracht T, Naylor SL. Human semaphorin 3B (SEMA3B) located at chromosome 3p21.3 suppresses tumor formation in an adenocarcinoma cell line. Cancer Res 2002;62:542-6. (Pubitemid 34106429)
22. Castro-Rivera E, Ran S, Thorpe P, Minna JD. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci U S A 2004;101:11432-7. (Pubitemid 39038364)
23. Kusy S, Nasarre P, Chan D, Potiron V, Meyronet D, Gemmill RM, et al. Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia 2005;7:457-65. (Pubitemid 40791865)
24. Jick SS, Walker AM, Jick H. Oral contraceptives and endometrial cancer. Obstet Gynecol 1993;82:931-5. (Pubitemid 23347989)
25. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006;95:385-9. (Pubitemid 44187603)
26. Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol 2006;103:535-40. (Pubitemid 44602164)
27. Rosenblatt KA, Thomas DB. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991;49:870-4.
28. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90:434-40. (Pubitemid 27357938)
29. Vereide AB, Kaino T, Sager G, Ørbo A. Scottish Gynaecological Clinical Trials Group. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2005;97:740-50. (Pubitemid 40824641)
30. Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002;94: 1867-75. (Pubitemid 34241126)
31. Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N, et al., Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1; Pten mutant mice. Clin Cancer Res 2006;12:5895-901. (Pubitemid 44629623)
32. Salazar-Martinez E, Lazcano-Ponce E, Sanchez-Zamorano LM, Gonzalez- Lira G, Escudero-De Los Rios P, et al. Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico. Int J Gynecol Cancer 2005;15:938-45. (Pubitemid 41783106)
33. Yu W, Cline M, Maxwell LG, Berrigan D, Rodriguez G, Warri A, et al. Dietary vitamin D exposure prevents obesity-induced increase in endometrial cancer in Pten+/- mice. Cancer Prev Res (Phila) 2010;3:1246-58.
34. Rodriguez GC, Rimel BJ, Watkin W, Turbov JM, Barry C, Du H, et al. Progestin treatment induces apoptosis and modulates transforming growth factor-beta in the uterine endometrium. Cancer Epidemiol Biomarkers Prev 2008;17:578-84. (Pubitemid 351469207)
35. Kyo S, Nakamura M, Kiyono T, Maida Y, Kanaya T, Tanaka M, et al. Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am J Pathol 2003;163: 2259-69. (Pubitemid 37466470)
36. Yabushita H, Hirata M, Noguchi M, Nakanishi M. Vitamin D receptor in endometrial carcinoma and the differentiation-inducing effect of 1,25- dihydroxyvitamin D3 on endometrial carcinoma cell lines. J Obstet Gynaecol Res 1996;22:529-39. (Pubitemid 27042086)
37. Syed V, Ulinski G, Mok SC, Ho SM. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst 2002; 94:617-29. (Pubitemid 34498649)
38. Cox AD, Der CJ. Biological assays for cellular transformation. Methods Enzymol 1994;238:277-94.
39. Ahmed N, Pansino F, Clyde R, Murthi P, Quinn MA, Rice GE, et al. Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis 2002;23:237-44. (Pubitemid 34223999)
40. Giavazzi R, Garofalo A, Ferri C, Lucchini V, Bone EA, Chiari S, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 1998;4:985-92. (Pubitemid 28183401)
41. Tomizawa Y, Sekido Y, Kondo M, Gao B, Yokota J, Roche J, et al. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci USA 2001;98:13954-9. (Pubitemid 33116005)
42. Osada R, Horiuchi A, Kikuchi N, Ohira S, Ota M, Katsuyama Y, et al. Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Hum Pathol 2006;37:1414-25. (Pubitemid 44584330)
43. Kigel B, Varshavsky A, Kessler O, Neufeld G. Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PLoS One 2008;3:e3287.
44. Marshall TG, Lee RE, Marshall FE. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model 2006;3:1-33.
45. Sutton AL, Zhang X, Dowd DR, Kharode YP, Komm BS, Macdonald PN. Semaphorin 3B is a 1,25-Dihydroxyvitamin D3-induced gene in osteoblasts that promotes osteoclastogenesis and induces osteopenia in mice. Mol Endocrinol 2008;22:1370-81. (Pubitemid 351786997)
46. Potiron VA, Sharma G, Nasarre P, Clarhaut JA, Augustin HG, Gemmill RM, et al. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Res 2007;67:8708-15. (Pubitemid 47437446)
47. Rolny C, Capparuccia L, Casazza A, Mazzone M, Vallario A, Cignetti A, et al. The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J Exp Med 2008;205:1155-71. (Pubitemid 351679690)
48. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 1995;147:33-41.
49. Sivridis E. Angiogenesis and endometrial cancer. Anticancer Res 2001;21:4383-8. (Pubitemid 34240969)
50. Karahan N, Guney M, Baspinar S, Oral B, Kapucuoǧlu N, Mungan T. Oral expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase- 2 (COX-2) in endometrial carcinoma. Eur J Gynaecol Oncol 2007;28:184-8. (Pubitemid 46985638)
51. Tunuguntla R, Ripley D, Sang QX, Chegini N. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer. Gynecol Oncol 2003;89:453-9. (Pubitemid 36687792)